Flashback! Psychedelic research returns
Kristof Kossut arrived at an unlikely address for his first psychedelic experience. The 60-year-old New Yorker and professional yachtsman opened the door not to an after-hours techno party, but to the bright reception room at the Bluestone Center for Clinical Research, a large spa-like space occupying the second floor of New York University’s College of Dentistry. Kossut was among the first subjects of an NYU investigation into the question: Can the mystical states of mind occasioned by psychedelic drugs help alleviate anxiety and depression in people with terminal and recurrent cancer?
Kossut had no idea, but in the spring of last year, he was looking for something, anything, that might improve his mental state. In 2008, he was diagnosed with cancer of the tonsils and put on a biweekly chemo and radiation regimen. He quickly lost his appetite, dropped weight and sank into a deep depression. When a friend sent him a news brief about the experimental NYU study, he applied.
Shortly before Kossut’s arrival on the morning of his session, two clinic employees entered a high-security storage room, which just happens to face a painting of a white rabbit. From a massive steel combination safe they removed a bottle containing one gram of synthesized psilocybin, the psychoactive agent animating the 200-member fungus family commonly known as “magic mushrooms.” The duo carefully measured the small container against the previous day’s weight, as if securing a store of weapons-grade plutonium. They then pill-pressed an amount of powder containing 20 milligrams of the molecule, first identified in 1958 by the Swiss chemist Albert Hoffman, most famous for his other psychedelic synthesis, LSD-25. Read ArticleBy Alexander Zaitchik